IBUPROFEN SODIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H17O2.Na.2H2O
Molecular Weight	264.2932
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.[Na+].CC(C)CC1=CC=C(C=C1)C(C)C([O-])=O

InChI

InChIKey=VTGPMVCGAVZLQI-UHFFFAOYSA-M

InChI=1S/C13H18O2.Na.2H2O/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15;;;/h4-7,9-10H,8H2,1-3H3,(H,14,15);;2*1H2/q;+1;;/p-1

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H18O2
Molecular Weight	206.2808
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20718179

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15481334	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Headache 47 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608	Palliative	Approved 8429	IBU-TAB Approved Use temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date 1988
Common cold 58 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608	Palliative	Approved 8429	IBU-TAB Approved Use temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date 1988
Muscular aches 12 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608	Palliative	Approved 8429	IBU-TAB Approved Use temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date 1988
Backache 16 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608	Palliative	Approved 8429	IBU-TAB Approved Use temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date 1988
Toothache 15 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608	Palliative	Approved 8429	IBU-TAB Approved Use temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date 1988

C_max

Value	Dose	Co-administered	Analyte	Population
27.9 μg/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/6465162	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		IBUPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
103 μg × h/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/6465162	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		IBUPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.2 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/6465162	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		IBUPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% REVIEW https://onlinelibrary.wiley.com/doi/10.1002/9781118743614.ch4			IBUPROFEN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
199800 mg single, oral Overdose Dose: 199800 mg Route: oral Route: single Dose: 199800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/18072160	unknown, 17 years Health Status: unknown Age Group: 17 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18072160	Other AEs: Cardiovascular collapse, Acidosis... Other AEs: Cardiovascular collapse (grade 5, 1 patient) Acidosis (grade 5, 1 patient) Hypothermia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18072160
90 g single, oral Overdose Dose: 90 g Route: oral Route: single Dose: 90 g Sources: https://pubmed.ncbi.nlm.nih.gov/20419362	unknown, 19 years Health Status: unknown Age Group: 19 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/20419362	Other AEs: Polyuria, Acidosis... Other AEs: Polyuria (1 patient) Acidosis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/20419362
800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21127424	unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: https://pubmed.ncbi.nlm.nih.gov/21127424	Other AEs: Acute respiratory distress syndrome, Tachypnea... Other AEs: Acute respiratory distress syndrome (serious, 1 patient) Tachypnea (serious, 1 patient) Septic shock (serious, 1 patient) Breathlessness (serious, 1 patient) Septicemia (serious, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/21127424
400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf Page: p.87	unhealthy, 42 years (range: 17-73 years) n = 195 Health Status: unhealthy Age Group: 42 years (range: 17-73 years) Sex: M+F Population Size: 195 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf Page: p.87	Disc. AE: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Dizziness (2%) Headache (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf Page: p.87
800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf Page: p.87	unhealthy, 44 years (range: 20-69 years) n = 304 Health Status: unhealthy Age Group: 44 years (range: 20-69 years) Sex: M+F Population Size: 304 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf Page: p.87	Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf Page: p.87
240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Co-administed with:: divalproex sodium Sources: https://pubmed.ncbi.nlm.nih.gov/18072160	unknown, 49 years Health Status: unknown Age Group: 49 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/18072160	Other AEs: Cardiovascular collapse... Other AEs: Cardiovascular collapse (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18072160
240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/18072160	unknown, 49 years Health Status: unknown Age Group: 49 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/18072160	Other AEs: Acidosis, Hypothermia... Other AEs: Acidosis (grade 5, 1 patient) Hypothermia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18072160
400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022348lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Pain Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022348lbl.pdf	Other AEs: Myocardial infarction, Stroke... Other AEs: Myocardial infarction (serious\|grade 5) Stroke (serious\|grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022348lbl.pdf
400 mg 6 times / day multiple, oral Recommended Dose: 400 mg, 6 times / day Route: oral Route: multiple Dose: 400 mg, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017463s105lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017463s105lbl.pdf	Other AEs: Myocardial infarction, Stroke... Other AEs: Myocardial infarction (serious\|grade 5) Stroke (serious\|grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017463s105lbl.pdf
200 mg single, oral Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01842633	unhealthy n = 62 Health Status: unhealthy Condition: Episodic Tension Type Headache Population Size: 62 Sources: https://clinicaltrials.gov/ct2/show/NCT01842633	Other AEs: Depression, Insomnia... Other AEs: Depression (below serious, 1 patient) Insomnia (below serious, 1 patient) Oropharyngeal pain (below serious, 1 patient) Sinus congestion (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01842633
97.5 mg 4 times / day multiple, oral Dose: 97.5 mg, 4 times / day Route: oral Route: multiple Dose: 97.5 mg, 4 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01420653	unhealthy n = 112 Health Status: unhealthy Condition: Dental Pain Population Size: 112 Sources: https://clinicaltrials.gov/ct2/show/NCT01420653	Other AEs: Facial swelling... Other AEs: Facial swelling (below serious, 8 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01420653
10 mg/kg single, oral Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: https://clinicaltrials.gov/ct2/show/NCT02241512	unhealthy n = 29 Health Status: unhealthy Condition: Post-ERCP Pancreatitis Population Size: 29 Sources: https://clinicaltrials.gov/ct2/show/NCT02241512	Other AEs: Bleeding, Perforation... Other AEs: Bleeding (below serious, 2 patients) Perforation (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02241512

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781	substrate 1037	substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461 OAT3 642 OAT1 599 OAT2 145 OAT4 146 OCT1 512 MRP2 383 Nav1.7 36	CYP2C8 693 CYP2C19 991 UGT1A3 422 UGT1A9 380 UGT2B4 249 UGT2B7 389 UGT2B17 213 UGT1A10 291 OATP1B1 406 OATP1B3 350 CYP1A2 1054 CYP2A6 543 CYP2E1 667 CYP4A11 119 UGT2B1 14

Drug as perpetrator

Target	Modality	Activity
MRP2 475	inhibitor 3277 Sources: https://www.jstage.jst.go.jp/article/dmpk/17/1/17_1_23/_article/-char/ja/ Page: 26.0	no
OAT3 644	inhibitor 3277 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/cts.12486 Page: abstract	yes [IC50 4.4 uM]
CYP3A4 1925	inducer 1573 Sources: https://www.tandfonline.com/doi/abs/10.3109/00498254.2014.955831 Page: 8.0	yes
Nav1.7 36	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/abs/pii/S152659000400762X Page: abstract	yes
OAT1 603	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
OAT2 147	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
OAT4 146	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
OCT1 543	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
P-gp 1650	inhibitor 3277 Sources: https://www.tandfonline.com/doi/abs/10.3109/14756366.2016.1149476 Page: 867.0	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1054	substrate 3367 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0006295297001433 Page: 37.0	minor
CYP2C19 991	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	minor
CYP2C8 693	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	minor
CYP2A6 543	substrate 3367 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0006295297001433 Page: 37.0	no
CYP2D6 1217	substrate 3367 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0006295297001433 Page: 37.0	no
CYP2E1 667	substrate 3367 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0006295297001433 Page: 37.0	no
CYP4A11 119	substrate 3367 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0006295297001433 Page: 37.0	no
OATP1B1 406	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	no
OATP1B3 350	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	no
CYP2C9 1037	substrate 3367 Sources: https://www.tandfonline.com/doi/abs/10.1517/17425255.2012.680886 Page: 701.0	yes
CYP3A4 1737	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
UGT1A10 291	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
UGT1A3 422	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
UGT1A9 380	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
UGT2B1 14	substrate 3367 Sources: https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=227797 Page: 2.0	yes
UGT2B17 213	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
UGT2B4 249	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes
UGT2B7 389	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355401/ Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.frontiersin.org/articles/10.3389/fphar.2012.00003/full Page: 5.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5855	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5855
ChemicalBook	CB3699656	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3699656
ChemicalBook	CB4336930	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4336930
ChemicalBook	CB92675917	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB92675917
MolPort	MolPort-001-791-802	https://www.molport.com/shop/molecule-link/MolPort-001-791-802
Selleck Chemicals	Ibuprofen(Advil)	http://www.selleckchem.com/products/Ibuprofen(Advil).html
eMolecules	539665	https://www.emolecules.com/cgi-bin/more?vid=539665

PubMed

Title	Date	PubMed
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.	1999 Dec 2	10602496
Topical non-steroidal drugs are systemically absorbed and may cause renal disease.	1999 Jan	10052505
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats.	1999 Jul	10422945
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.	1999 Jun	10336562
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes.	1999 May	10328874
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.	1999 Nov-Dec	10697514
The effect of spinal ibuprofen on opioid withdrawal in the rat.	2000 Aug	10910860
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.	2000 Feb 11	10660625
Regulation of endothelial nitric oxide synthase by PGD(2) in the developing choroid.	2000 Jan	10644584
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.	2000 Jan	10625080
Ibuprofen as effective as indomethacin for patent ductus arteriosus.	2000 Jul 25	10908230
R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production.	2000 Jun	10903797
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells.	2000 Nov 17	11080519
[Ibuprofen-induced, transient ANA- and anti-histone positive leukocytoclastic vasculitis].	2000 Sep	11057395
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.	2001	11296921
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.	2001	11228592
[Misuse of drugs in recreational sports].	2001 Apr	11344954
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.	2001 Apr	11341362
Obsessive-compulsive disorder: a neuronal membrane phospholipid hypothesis and concomitant therapeutic strategy.	2001 Apr	11339839
In vitro effect of different non-steroidal anti-inflammatory drugs on human polymorphonuclear leukocyte activity measured by luminol-dependent chemiluminescence of the whole blood.	2001 Apr	11331497
Ibuprofen-induced bullous leukocytoclastic vasculitis.	2001 Apr	11324392
Induced accumulation of 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one glucoside (HDMBOA-Glc) in maize leaves.	2001 Apr	11314951
Nonsurgical female sterilization: comparison of intrauterine application of quinacrine alone or in combination with ibuprofen.	2001 Apr	11287047
Investigational COX-2 inhibitor relieves pain in dental model.	2001 Feb	11320990
The use of anti-inflammatory drugs in cancer pain.	2001 Feb	11237777
The involvement of phospholipase A(2) in ethanol-induced gastric muscle contraction.	2001 Feb 16	11226404
The role of acetaminophen in the management of patients with osteoarthritis.	2001 Feb 19	11173050
Functional evidence for an inward rectifier potassium current in rat renal afferent arterioles.	2001 Feb 2	11157666
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.	2001 Feb 23	11263577
Ibuprofen for closure of patent ductus arteriosus.	2001 Jan	11124795
Ibuprofen as a chemesthetic stimulus: evidence of a novel mechanism of throat irritation.	2001 Jan	11124216
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.	2001 Jan 10	11231885
Penetration enhancement of ibuprofen from supersaturated solutions through human skin.	2001 Jan 5	11165828
Allergic reactions due to ibuprofen in children.	2001 Jan-Feb	11207978
Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals.	2001 Mar	11259508
Audit of pain management at home following tonsillectomy in children.	2001 Mar	11244527
Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water.	2001 Mar 16	11293584
Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella.	2001 May	11331694
Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations.	2001 May 1	11318639
Chemical reactivity in solid-state pharmaceuticals: formulation implications.	2001 May 16	11325479

Patents

Sample Use Guides

In Vivo Use Guide

adults: take 1 tablet every 4 to 6 hours while symptoms persist. If pain or fever does not respond to 1 tablet, 2 tablets may be used; do not exceed 6 tablets in 24 hours. Children under 12 years: ask a doctor.

Route of Administration: Oral

In Vitro Use Guide

Ibuprofen, in a 400-μM concentration, decreased the expression of Hsp70 by 23% in comparison with untreated cells, whereas other NSAID had no effect. Ibuprofen also decreased the expression of Hsp70 in H358, a human lung adenocarcinoma cell line, in a dose-dependent manner (from 0-400 uM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:38:43 GMT 2023` Edited by `admin` on `Fri Dec 15 18:38:43 GMT 2023`
Record UNII	RM1CE97Z4N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IBUPROFEN SODIUM

Official Name

English

Ibuprofen sodium [WHO-DD]

Common Name

English

Sodium (2RS)-2-[4-(2-methylpropyl)phenyl]propanoate dihydrate

Systematic Name

English

COMBOGESIC IV COMPONENT IBUPROFEN SODIUM

Brand Name

English

IBUPROFEN SODIUM [USAN]

Common Name

English

BENZENEACETIC ACID, .ALPHA.-METHYL-4-(2-METHYLPROPYL)-, SODIUM SALT, HYDRATE (1:1:2)

Common Name

English

IBUPROFEN SODIUM [ORANGE BOOK]

Common Name

English

IBUPROFEN SODIUM DIHYDRATE

Common Name

English

SODIUM IBUPROFEN DIHYDRATE

Common Name

English

Code System Code Type Description

PUBCHEM

23690315